Contact Us marketing@medicilon.com
Medicilon Logo
|
search icon search icon 中 contact icon menu icon
Medicilon Logo
|
search icon close search icon 中 contact icon menu icon
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
Over 20 years of experience in R&D
Learn more
01 Drug Discovery
Chemistry Research
Biology Research
Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates
Active Pharmaceutical Ingredients
Pharmaceutical preparation
Analytical Method Development and Quality Control
CMC Filings
Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics
Drug Safety Evaluation
DMPK
Bioanalysis
IND Filings
01 One-stop Integrated Services
Liposome Drug Development
Drug Discovery
Pharmaceutical Research
Preclinical Research
Botanical Drug Preclinical R&D
02 Innovative Drug Services
ADC
PROTAC
mRNA Vaccine
Cellular Immunotherapies
Nucleic Acid Drug
Peptide Drug Conjugate (PDC)
Antibody
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection
Metabolite Identification (MetID)
Drug Forming Research
Flow Cytometry Technology
SEND Format Conversion
Flow Sorting
NanoString nCounter Detection
Routes of Drug Administration
04 Drug Efficacy Evaluation for Common Diseases
IO Pharmacodynamic Model
Inflammatory and Immune Diseases
Rodent Cerebrovascular Disease
05 Advanced Preparation R&D
Inhalation drug
Ophthalmic drug
Skin Topical Preparation
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service
GLP-1 New Drug R&D Service
KRAS-targeted Drugs R&D Service
CAREERS
Talent Development
Campus Recruitment
Recruitment
Campus Recruitment
Campus Recruitment
Recruitment
Recruitment
News
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
2024-07-22Medicilon Events
The Shanghai Overseas Returned Scholars Association invites the Dutch PhD delegation to visit Medicilon, exploring paths for innovative development together
On July 4th, the Shanghai Overseas Returned Scholars Association invited the Dutch PhD delegation to visit the Chuansha campus of Shanghai Medicilon Inc. (Medicilon) and held discussions with Medicilon's Founder and CEO, Chunlin Chen, among others.
Learn more
2024-07-22Medicilon Events
5th consecutive win! Medicilon once again made the list of "Top 20 Chinese R&D CRO Enterprises in 2024"
Medicilon stood out among hundreds of pharmaceutical enterprises and was honored with the "Top 20 Chinese R&D CRO Enterprises in 2024" award.
Learn more
INVESTORS
Stock Information
Investment Contact
Medicilon 688202
RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
U.S.

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(626)986-9880

UK

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Close

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888 | Website Map

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888|Website Map
关闭
中
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events
Medicilon Events Featured Stories Market Events Videos A.C.E.
HomenewsMedicilon Events

Medicilon Events

Hot information：
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon| Medicilon FTE services & FFS services - flexible and efficient cooperation model
Jan 22,2024
Empowering two pipelines with dual reporting and batching in China and the United States - Medicilon won the "2023 Best Partner Award" from Gluetacs Therapeutics
On January 8, Dr. Xiaobao Yang, Chairman and CEO of Gluetacs Therapeutics (Gluetacs) awarded Shanghai Medicilon Inc. (Medicilon) the "2023 Best Partner Award”. Dr. Jinna Cai, Chief Commercial Officer of Medicilon, and Bolin Zhang, Director of CMC of Key Account Development Department, attended the award ceremony.
More
Empowering two pipelines with dual reporting and batching in China and the United States - Medicilon won the "2023 Best Partner Award" from Gluetacs Therapeutics
Jan 08,2024
Medicilon Summary for 2023
As an enabler of the pharmaceutical industry, Medicilon adheres to its original mission, works hard and moves forward resolutely, writing Medicilon's "answer"for 2023!
More
Medicilon Summary for 2023
Jan 05,2024
Three years in a row! Medicilon once again appears on the 2023 "Influential Preclinical CRO Enterprises of the Year" list
On December 15, the 4th China Biopharmaceutical Industry Chain Innovation and Transformation Summit and the 4th China Biopharmaceutical Innovation Billboard Awards Ceremony were grandly held in Hangzhou. This is the third consecutive year that Medicilon has won this award!
More
Three years in a row! Medicilon once again appears on the 2023 "Influential Preclinical CRO Enterprises of the Year" list
Jan 05,2024
Medicilon signed a strategic collaboration agreement with the North American 100 Angel Investment
On December 22, 2023, Medicilon and North America 100 Angel Investment LLC announced that the two parties had officially signed a strategic collaboration agreement in Boston. This collaboration will bring huge opportunities to both parties and promote the global development of both parties in the field of innovative drug research and development.
More
Medicilon signed a strategic collaboration agreement with the North American 100 Angel Investment
Jan 04,2024
Medicilon appoints Dr. Zhang Haizhou as President of Preclinical R&D Unit
Recently, Medicilon appoints Dr. Zhang Haizhou as President of Preclinical R&D Unit. Dr. Zhang Haizhou holds a PhD in Toxicology from Indiana University, USA. He is a pharmaceutical industry veteran with over 20 years of experience in the R&D of small and large molecule drugs.
More
Medicilon appoints Dr. Zhang Haizhou as President of Preclinical R&D Unit
Dec 29,2023
Medicilon Interview with Dr. Wenbo Zhou | Focusing on difficult-to-drug targets, three INDs have been approved in three years. What are the advantages of Yuyao Biotech?
Medicilon conducted an exclusive interview with Dr. Wenbo Zhou, the founder of Yuyao Biotech. The clinical trial of YY201, the world's first STAT3 small molecule inhibitor by Yuyao Biotech, has been officially approved by the US FDA.
More
Medicilon Interview with Dr. Wenbo Zhou | Focusing on difficult-to-drug targets, three INDs have been approved in three years. What are the advantages of Yuyao Biotech?
Dec 29,2023
Medicilon Interview with Dr. Yifan Zhan | CD73 targeted therapy has ushered in a new dawn, revealing the research history and future prospects of Huaota Biopharmaceutical
In the field of immunotherapy, CD73, an immune regulatory molecule, has attracted much attention in recent years. Medicilon had the honor to interview Dr. Yifan Zhan, Chief Scientist of Huaota.
More
Medicilon Interview with Dr. Yifan Zhan | CD73 targeted therapy has ushered in a new dawn, revealing the research history and future prospects of Huaota Biopharmaceutical
Dec 28,2023
Medicilon was awarded the "Industry Outstanding Member Unit Management Award" by the China Laboratory Primate Breeding and Development Association
Recently, the China Laboratory Primate Breeding and Development Association Industry Academic Exchange Conference and 30th Anniversary Celebration were held as scheduled at the Dragon Lake Princess Hotel in Huadu, Guangzhou. As a member, Shanghai Medicilon Inc. was invited to attend the conference and was awarded the "Industry Outstanding Member Unit Management Award".
More
Medicilon was awarded the "Industry Outstanding Member Unit Management Award" by the China Laboratory Primate Breeding and Development Association
Dec 22,2023
Pharmalego intermediates e-commerce platform launched; We have what scientific researchers are struggling to find
From a one-stop biopharmaceutical preclinical R&D service platform, to Medicilon Academician Innovative Drug Maturation Center and New Drug Ecological Assistance Platform, to building a pharmaceutical network (PharmalegoTM), Medicilon is willing to help you overcome the obstacles on the journey of new drug research and development.
More
Pharmalego intermediates e-commerce platform launched; We have what scientific researchers are struggling to find
Dec 12,2023
Build a new drug empowerment ecosystem, Medicilon Academician Innovative Drug Maturation Center - New Drug Ecological Assistance Platform Press Conference was successfully completed
On November 30, the "Focus on the development of innovative drugs and promote the upgrading of the industrial chain - Medicilon Academician Innovative Drug Maturation Center - New Drug Ecological Assistance Platform Press Conference" hosted by Shanghai Medicilon Inc. (Medicilon) was grandly held.
More
Build a new drug empowerment ecosystem, Medicilon Academician Innovative Drug Maturation Center - New Drug Ecological Assistance Platform Press Conference was successfully completed
Nov 28,2023
Dr. Liu Jian, President of Medicilon Drug Discovery Division, wins the Thomas Alva Edison Patent Award
Dr. Liu Jian, President of the Drug Discovery Division at Medicilon, has been awarded the Thomas Alva Edison Patent Award for 2023 from the New Jersey Research and Development Committee.
More
Dr. Liu Jian, President of Medicilon Drug Discovery Division, wins the Thomas Alva Edison Patent Award
Oct 25,2023
Medicilon congratulated AnDiCon Biotech collaborated with Simcere Pharmaceuticals to accelerate the commercialization of a new generation of anti-influenza drug ADC189
On October 10, 2023, Simcere Pharmaceutical Group Ltd. (2096.HK) announced that they entered into a collaboration agreement with Jiaxing AnDiCon Biotech Co., Ltd. (AnDiCon) on the anti-influenza innovative drug ADC189.
More
Medicilon congratulated AnDiCon Biotech collaborated with Simcere Pharmaceuticals to accelerate the commercialization of a new generation of anti-influenza drug ADC189
Stock Code
688202

Global

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(626)986-9880(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->